A Prospective Open-label Study Evaluating Retinal Nerve Fibre Layer (RNFL) Thickness In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 17 Sep 2016 Results of this study, presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 02 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology